DrugPatentWatch Database Preview
XIIDRA Drug Profile
see a sample report or, see our see our flat-rate plans
When do Xiidra patents expire, and what generic alternatives are available?
This drug has ninety-seven patent family members in twenty-one countries.
The generic ingredient in XIIDRA is lifitegrast. One supplier is listed for this compound. Additional details are available on the lifitegrast profile page.
Summary for XIIDRA
| International Patents: | 97 |
| US Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 18 |
| Patent Applications: | 45 |
| DailyMed Link: | XIIDRA at DailyMed |
Pharmacology for XIIDRA
| Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
| Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Synonyms for XIIDRA
| (2S)-2-(((2-(Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid |
| (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido |
| 038E5L962W |
| 1025967-78-5 |
| 1356856-75-1 |
| 915397-62-5 |
| AKOS030628489 |
| BDBM50386331 |
| CHEBI:133023 |
| CHEMBL2048028 |
| compound 1g [PMID: 24900456] |
| CS-6264 |
| D04ISS |
| D0Q9EV |
| D10374 |
| DB11611 |
| DTXSID60145345 |
| Dual leukocytefunction-associated antigen-1/intracellular adhesion molecule-1 inhibitors (inflammatory diseases), SARcode |
| Dual LFA-1/ICAM-1 inhibitors (inflammatory diseases), SARcode |
| Dual LFA-1/ICAM-1 inhibitors, Sunesis |
| GTPL7533 |
| HY-19344 |
| L-Phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- |
| Lifitegrast |
| Lifitegrast (USAN/INN) |
| Lifitegrast [USAN:INN] |
| MolPort-044-727-763 |
| N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-L-phenylalanine |
| SAR 1118 |
| SAR 1118-023 |
| SAR-1118 |
| SAR-1119 |
| SAR1118 |
| SCHEMBL2632068 |
| SHP606 |
| SPD606 |
| UNII-038E5L962W |
| Xiidra (TN) |
| ZINC84668739 |
US Patents and Regulatory Information for XIIDRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for XIIDRA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,080,562 | Crystalline pharmaceutical and methods of preparation and use thereof | ➤ Sign Up |
| 9,045,457 | Compositions and methods for treatment | ➤ Sign Up |
| 7,989,626 | Modulators of cellular adhesion | ➤ Sign Up |
| 8,871,935 | Crystalline pharmaceutical and methods of preparation and use thereof | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for XIIDRA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2614080 | ➤ Sign Up |
| China | 105820160 | ➤ Sign Up |
| Russian Federation | 2015102926 | ➤ Sign Up |
| China | 102065694 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
